News

Maybelline New York names Yadim Carranza as global makeup artist

BY Antoinette Alexander

NEW YORK — Maybelline New York has named Yadim Carranza as the brand’s global makeup artist, providing artistic vision for Maybelline New York makeup and becoming the voice of the brand to consumers, press and industry influencers. 

"We are incredibly excited to partner with Yadim," stated Jerome Bruhat, president, Maybelline New York worldwide. "Yadim will add a new energy and urban edge to the brand in both his artistry and expertise in global beauty trends.  His instinctive sense of color coupled with his ability to connect with our consumer will create a brand experience in a disruptive new way."

Carranza has worked backstage with Maybelline New York, having led a team of makeup artists at fashion shows for DKNY, Charlotte Ronson and Bibhu Mohapatra during Mercedes-Benz Fashion Week in New York this past February.

A Mexican-American native of California, Carranza began his career behind a makeup counter, transforming and educating women through makeup application. Carranza’s passion and talent were quickly discovered, and after moving to New York City, his career was fostered by some of the biggest names in the fashion and beauty industry.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Study: Increasing dietary fiber could save healthcare $12.7 billion

BY Michael Johnsen

BATTLE CREEK, Mich. — A new health economic study shows potential healthcare savings of $12.7 billion per year if U.S. adults would increase their dietary fiber to about 25 grams, the minimum level recommended by health experts for adults. Currently, less than 1-in-10 Americans meet their daily fiber needs.

"With the rising cost of health care, this research highlights the importance of simple, realistic changes that we can make to our diet, such as eating more fiber, which could contribute to significant health care savings," stated Dominik Alexander, a  principal epidemiologist, who managed the research team conducting the study.

The study, carried out by an independent team of researchers in nutritional sciences, epidemiology, and health economics from Exponent Health Sciences and commissioned by Kellogg Co., evaluated the direct medical costs associated with regularity problems among adults in the U.S. The research team developed a model to determine the potential money that could be saved through preventive, lifestyle-related measures, in this case, increasing dietary fiber intake.   

Also according to the study, if only half of the U.S. population increased their dietary fiber intake by just three grams a day there could still be more than $2 billion in health care cost savings.

"This goal could be easily achieved with just one or two simple dietary changes," noted Lisa Sanders, director, global nutrition and scientific affairs at Kellogg Co.. "Selecting a higher fiber cereal for breakfast and having a piece of fruit or higher fiber snack bar later in the day could supply three grams of fiber, or even more."

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

GSK, Novartis create an $11 billion consumer healthcare business

BY Michael Johnsen

LONDON — Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis. The new business, to be called GSK Consumer Healthcare, will hold category leading positions and brands in wellness, oral health, nutrition and skin health, the company reported.

“The Novartis OTC portfolio is highly complementary to GSK’s and has many well-known, widely recommended brands, such as Voltaren, Excedrin, Otrivin and Theraflu," stated Sir Andrew Witty, GSK CEO. "Together, we will create the world’s premier OTC business with clear opportunities to accelerate revenue growth."

Emma Walmsley, currently GSK’s consumer head, has been appointed as CEO designate of the new business and will be a member of its board. Witty will be chairman of the board. The board will comprise directors from both GSK and Novartis. 

GSK will have majority control of the joint venture with an equity interest of 63.5%

In wellness, the new combination’s $5.7 billion complementary portfolio will create one of the world’s largest OTC businesses with a leading position in more than 35 countries. According to GSK, Novartis’ portfolio has had relatively limited exposure to high growth emerging markets and this presents multiple new growth opportunities for several major brands and innovations, notably Voltaren, Excedrin and Otrivin. 

Similarly, GSK’s brands would benefit from exposure to Novartis’ highly successful European businesses. 

According to a Wall Street Journal breakdown of the deal, "some of the new company’s biggest products will be in pain and cold relief: the North American brand Excedrin and the European brands Panadol, Beecham’s and Voltaren gel, for migraines, headaches, colds and joint pain. Antismoking aids NicoDerm, NiQuitin and Nicotinell, in gums, lozenges and patches, will also be key products." The Novartis business will also bring such products as cough suppressant Sinecod, nasal decongestant Otrivin and fiber supplement Benefiber.

The second-largest area for the combined business will be oral care, according to the WSJ report, including Sensodyne and Aquafresh toothpastes and Poligrip denture adhesive. 

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?